Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.
about
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.Malaria parasite LIMP protein regulates sporozoite gliding motility and infectivity in mosquito and mammalian hosts.Developing transmission-blocking strategies for malaria control.Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated HostsNK Cells: Uncertain Allies against Malaria.Development of replication-deficient adenovirus malaria vaccines.HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8+ T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria.Recombinant vaccines of a CD4+ T-cell epitope promote efficient control of Paracoccidioides brasiliensis burden by restraining primary organ infection.Investigating Bordetella pertussis colonisation and immunity: protocol for an inpatient controlled human infection model.Controlled Human Malaria Infection: Applications, Advances and Challenges.Novel Plasmodium antigens identified via genome-based antibody screen induce protection associated with polyfunctional T cell responses.Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage.Development of novel vaccine vectors: Chimpanzee adenoviral vectors.Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens.Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype.Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.Hepatitis C Vaccines, Antibodies, and T Cells.Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral VectorsQualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Circumsporozoite Protein AntigensCXCR3 T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against MalariaMalaria Vaccines: Recent Advances and New HorizonsActivation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical TrialsSafety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAPAntibodies against adenovirus fiber and penton base proteins inhibit adenovirus vector-mediated transduction in the liver following systemic administration
P2860
Q33577093-38BD21F7-273E-4351-BD7C-FE6A78D73B8EQ33708234-CE78CF7E-49D5-4D0F-B372-6CC9CC35480CQ33880789-5CDF3841-A1AB-4C0D-AD5A-53251F0DCAF4Q36225504-7BA32324-03EE-4A66-BD03-01FE4C5323F9Q36247867-27851C83-59DB-4F23-B9C1-77A0C64B2C04Q37689434-20CF49A3-20DA-4187-8DC7-048F32EC62EAQ38949194-6FCE09EA-74E9-4EF6-A75A-EB1D4C612132Q40089181-508781C4-38BE-4634-ABAF-06AB45F60866Q40290590-4707AAE8-3AEE-4B8B-BD59-029C11A4571BQ41932144-618C312B-3DFD-4553-B964-82F00F9DEFE3Q42650053-8AB455A0-F81F-49B4-B2BD-8E096C8ECC93Q44168331-59A394C8-BAD8-491F-9B12-FEFFE0342310Q47154921-68E4C832-17A4-4B33-BFA7-6861486161B3Q47202176-952E0D46-04DD-478A-8B6D-D3580C421493Q47558190-0C472BA8-4CDC-4501-A128-96400F415D15Q47558367-5EBE3FF7-8111-4455-80AB-0065E71C873AQ47581449-2921D403-3968-41EB-B0B3-3BA22E15C5A9Q48018507-D499E32F-D25D-4770-AB4A-0B5381E0A7C5Q48022505-F8F2E480-161B-4620-B71B-12099FAF4A7CQ50029763-C649C68A-17A6-46A7-A69C-6FCCE677C78CQ50347547-9758AF99-F8EE-4890-A888-3046E9FCD827Q55709137-E81681C8-9DE3-4DE5-A90C-DDD60BCFA0BEQ56341814-92B04949-2B93-42FB-B972-BF582A0A639AQ56342409-322D95C5-60F3-4210-BD20-C358D63062A1Q56357275-BA91740C-6390-4C50-940E-F89F7B9C4D2DQ56362064-BEFB2EF1-1E06-42B5-A93A-294233807996Q57078159-6DCC72E5-CF9D-45C3-987E-C3C9FEB38A46Q57480738-70A4964E-371A-48FB-8D22-241E7C453860Q58770917-D72564C9-8F93-4B2D-97F2-EA4C10903697
P2860
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and High Level Efficacy ...... d Vaccines Expressing ME-TRAP.
@en
Safety and High Level Efficacy ...... d Vaccines Expressing ME-TRAP.
@nl
type
label
Safety and High Level Efficacy ...... d Vaccines Expressing ME-TRAP.
@en
Safety and High Level Efficacy ...... d Vaccines Expressing ME-TRAP.
@nl
prefLabel
Safety and High Level Efficacy ...... d Vaccines Expressing ME-TRAP.
@en
Safety and High Level Efficacy ...... d Vaccines Expressing ME-TRAP.
@nl
P2093
P2860
P50
P356
P1476
Safety and High Level Efficacy ...... d Vaccines Expressing ME-TRAP.
@en
P2093
Alison M Lawrie
Bebi-Yassin Rajkumar
Carly M Bliss
Christian F Ockenhouse
Claudia M Snudden
Cynthia K Lee
Danielle Morelle
Eoghan de Barra
Graham S Cooke
Hans de Graaf
P2860
P304
P356
10.1093/INFDIS/JIW244
P407
P50
P577
2016-06-15T00:00:00Z